Title |
KRAS as a Therapeutic Target
|
---|---|
Published in |
Clinical Cancer Research, April 2015
|
DOI | 10.1158/1078-0432.ccr-14-2662 |
Pubmed ID | |
Authors |
Frank McCormick |
Abstract |
KRAS proteins play a major role in human cancer, but have not yielded to therapeutic attack. New technologies in drug discovery and insights into signaling pathways that KRAS controls have promoted renewed efforts to develop therapies through direct targeting of KRAS itself, new ways of blocking KRAS processing, or by identifying targets that KRAS cancers depend on for survival. Although drugs that block the well-established downstream pathways, RAF-MAPK and PI3K, are being tested in the clinic, new efforts are under way to exploit previously unrecognized vulnerabilities, such as altered metabolic networks, or novel pathways identified through synthetic lethal screens. Furthermore, new ways of suppressing KRAS gene expression and of harnessing the immune system offer further hope that new ways of treating KRAS are finally coming into view. These issues are discussed in this edition of CCR Focus. Clin Cancer Res; 21(8); 1797-801. ©2015 AACR. See all articles in this CCR Focus section, "Targeting RAS-Driven Cancers." |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 67% |
Unknown | 1 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | <1% |
United Kingdom | 1 | <1% |
Germany | 1 | <1% |
Japan | 1 | <1% |
Spain | 1 | <1% |
Unknown | 353 | 98% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 73 | 20% |
Student > Ph. D. Student | 68 | 19% |
Student > Bachelor | 53 | 15% |
Student > Master | 29 | 8% |
Student > Doctoral Student | 22 | 6% |
Other | 49 | 14% |
Unknown | 66 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 83 | 23% |
Agricultural and Biological Sciences | 78 | 22% |
Medicine and Dentistry | 46 | 13% |
Chemistry | 23 | 6% |
Pharmacology, Toxicology and Pharmaceutical Science | 21 | 6% |
Other | 34 | 9% |
Unknown | 75 | 21% |